FY2026 · ended Jan 31, 2026 · Revenue $0 · Filed Jun 17, 2026
Vitaspring Biomedical Co., Ltd. (VSBC) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2026, which ended Jan 31, 2026, it reported revenue of $0 and a net loss of $415,368.
Revenue (TTM)
$0
Net income (TTM)
$-455,643
+14.2% vs year-ago TTM
Operating cash flow (TTM)
$10,568
+203.6% vs year-ago TTM
Free cash flow
$-77,556
+77.4% vs prior year
EPS (TTM)
$-0.00
+14.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
207.03M
+0.0% vs prior year
Net cash
$2,084
FY 2026
Operating margin
20.1%
FY 2021
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- VSBC (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- NV
- Headquarters
- Riverside, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1697884
- Former names
- Shemn Corp. (until Apr 27, 2020)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jan 31, 2026 |
FY 2025 Jan 31, 2025 |
FY 2024 Jan 31, 2024 |
FY 2023 Jan 31, 2023 |
FY 2021 Jan 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $5.6M |
| Operating income | -$385,411 | -$679,914 | -$1.1M | -$4.2M | $1.1M |
| Net income | -$415,368 | -$774,922 | -$1.1M | -$4.2M | $909,560 |
| Diluted EPS | $0.00 | $0.00 | -$0.01 | -$0.02 | — |
| Operating cash flow | -$2,688 | -$14,675 | -$34,920 | -$77,556 | -$269,631 |
| Free cash flow | — | — | — | -$77,556 | -$342,628 |
| Total assets | $14,676 | $14,378 | $137,342 | $765,948 | $3.6M |
| Total liabilities | $4.4M | $4.0M | $3.5M | $3.2M | $2.0M |
| Stockholders' equity | -$4.4M | -$4.0M | -$3.4M | -$2.4M | $1.6M |
| Cash and investments | $2,084 | $272 | $13 | $29,656 | $107,212 |
| Total debt | $0 | $0 | $93,334 | $262,981 | $479,495 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 17, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 10, 2026 | Sep 7, 2026 |
| 10-K | Annual report | Jun 17, 2026 | Jan 31, 2026 |
| 10-Q | Quarterly report | Jun 17, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | Jun 17, 2026 | Oct 31, 2025 |
| 10-Q | Quarterly report | Jun 17, 2026 | Jul 31, 2025 |
All 74 Vitaspring Biomedical Co., Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.